위장판 : 대장암세포주 HT-29 세포에서 Saccharomyces boulardii에 의한 Peroxisome Proliferator-activated Receptor-γ 발현의 회복 = ALIMENTARY : Saccharomyces boulardii Activates Expression of Peroxisome Proliferator-activated Receptor-γ in HT-29 Cells

다국어 초록 (Multilingual Abstract)

Background/Aims: Saccharomyces boulardii (S. boulardii) has been reported to be beneficial in the treatment of inflammatory bowel disease, however, little is known about its mechanism of action. Peroxisome proliferator- activated receptor-γ (PPAR-γ) is re

참고문헌 (Reference)

1 Plein K, "Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea pilot study" 31 : 129-134, 1993

2 Surawicz CM, "The search for a better treatment for recurrent Clostridium difficile disease:use of high-dose vancomycin combined with Saccharomyces boulardii" 31 : 1012-1017, 2000

3 Ricote M, "The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation" 391 : 79-82, 1998

4 Castagliuolo I, "Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum" 64 : 5225-5232, 1996

5 Sougioultzis S, "Saccharomyces boulardii produces a soluble factor that inhibits NF-kB mediated IL-8 gene expression" 125 : 606-, 2003

6 Czerucka D, "Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells" 68 : 5998-6004, 2000

7 Guslandi M, "Saccharomyces boulardii in maintenance treatment of Crohn's disease" 45 : 1462-1464, 2000

8 Neish AS, "Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination" 289 : 1560-1563, 2000

9 Mack DR, "Probiotics inhibit enteropathogenic E.coli adherence in vitro by inducing intestinal mucin gene expression" 276 : 941-950, 1999

10 Fuller R, "Probiotics in man and animals" 66 : 365-378, 1989

11 Goossens D, "Probiotics in gastroenterology:indications and future perspectives" 239 : 15-23, 2003

12 Madsen K, "Probiotic bacteria enhance murine and human intestinal epithelial barrier function" 121 : 580-591, 2001

13 Toothaker RD, "Prevention of clindamycin-induced mortality in hamsters by Saccharomyces boulardii" 26 : 552-556, 1984

14 Schoonjans K, "Peroxisome proliferator-activated receptors,orphans with ligands and functions" 8 : 159-166, 1997

15 Lefebvre M, "Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells" 162 : 331-340, 1999

16 Jiang C, "PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines" 391 : 8286-, 1998

17 Haller D, "Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leukocyte co-cultures" 47 : 79-87, 2000

18 Helgeland L, "Microbial colonization influences composition and T-cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine" 89 : 494-501, 1996

19 Wu GD, "Is there a role for PPAR gamma in IBD? Yes, no, maybe" 124 : 1538-1542, 2003

20 Dubuquoy L, "Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis" 124 : 1265-1276, 2003

21 Venturi A, "Impact on the composition of the faecal flora by a new probiotic preparation:preliminary data on maintenance treatment of patients with ulcerative colitis" 13 : 1103-1108, 1999

22 Nakajima A, "Endogenous PPAR gamma mediates anti-inflammatory activity in murine ische-mia-reperfusion injury" 120 : 460-469, 2001

23 Czerucka D, "Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl secretion in T84 cells" 44 : 2359-2368, 1999

24 Flynn S, "Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118" 148 : 973-984, 2002

25 Desreumaux P, "Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies" 193 : 827-838, 2001

26 McFarland LV, "A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease" 271 : 1913-1918, 1994

27 Guslandi M, "A pilot trial of Saccharomyces boulardii in ulcerative colitis" 15 : 697-698, 2003

28 Su CG, "A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response" 104 : 383-389, 1999